Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions


Thakur, Kiran T, Tamborska, Arina ORCID: 0000-0003-4661-8407, Wood, Greta K ORCID: 0000-0001-6098-2331, McNeill, Emily, Roh, David, Akpan, Imo J, Miller, Eliza C, Bautista, Alyssa, Claassen, Jan, Kim, Carla Y et al (show 11 more authors) (2021) Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions. Journal of the Neurological Sciences, 427. p. 117532.

[img] Text
PIIS0022510X21002264.pdf - Published version
Download (1MB) | Preview

Abstract

<h4>Background</h4>Vaccine induced immune mediated thrombocytopenia or VITT, is a recent and rare phenomenon of thrombosis with thrombocytopenia, frequently including cerebral venous thromboses (CVT), that has been described following vaccination with adenovirus vaccines ChAdOx1 nCOV-19 (AstraZeneca) and Ad26.COV2·S Johnson and Johnson (Janssen/J&J). The evaluation and management of suspected cases of CVT post COVID-19 vaccination are critical skills for a broad range of healthcare providers.<h4>Methods</h4>A collaborative comprehensive review of literature was conducted among a global group of expert neurologists and hematologists.<h4>Findings</h4>Strategies for rapid evaluation and treatment of the CVT in the context of possible VITT exist, including inflammatory marker measurements, PF4 assays, and non-heparin anticoagulation.

Item Type: Article
Uncontrolled Keywords: Cerebral venous thrombosis, COVID-19, Vaccination
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences
Depositing User: Symplectic Admin
Date Deposited: 15 Jun 2021 07:56
Last Modified: 18 Jan 2023 22:34
DOI: 10.1016/j.jns.2021.117532
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3126308
Dimensions
Altmetric
CORE (COnnecting REpositories)